Novavax Stock More Than Doubles, Hits 52-Week Highs After Sanofi Deal

Novavax Inc. ($NVAX) has seen a significant increase in its stock price, hitting 52-week highs following a deal with Sanofi ($SNF). The stock more than doubled from its initial selloff after the agreement, marking a notable turnaround for the company. Analysts have projected further growth, with potential price targets of 23-24, 35, and possibly 51 before the end of July, and 180 sometime into late 2025-2026. The stock's performance has been closely monitored by market observers.